Valeant Pharma (VRX) Reports Q3 EPS of $2.11

Valeant Pharma (NYSE: VRX) reported Q3 EPS of $2.11, versus $1.43 reported last year. Revenue for the quarter came in at $2.06 billion, versus $1.54 billion reported last year.

Analysts were looking for EPS of $1.99.

Valeant sees FY14 cash EPS of $8.22 to $8.32 and Q4 EPS from $2.45 to $2.55. The company was previously looking for FY14 EPS of $7.90 to $8.10.

For earnings history and earnings-related data on Valeant Pharma (VRX) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
• RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)